RESUMEN
Cystic fibrosis (CF) is a genetic and multisystemic disease that requires a high therapeutic demand for its control. The aim of this study was to assess therapeutic adherence (TA) to different treatments to study possible clinical consequences and clinical factors influencing adherence. This is an ambispective observational study of 57 patients aged over 18 years with a diagnosis of CF. The assessment of TA was calculated using the Medication Possession Ratio (MPR) index. These data were related to exacerbations and the rate of decline in FEV1 percentage. Compliance was good for all CFTR modulators, azithromycin, aztreonam, and tobramycin in solution for inhalation. The patients with the best compliance were older; they had exacerbations and the greatest deterioration in lung function during this period. The three variables with the highest importance for the compliance of the generated Random Forest (RF) models were age, FEV1%, and use of Ivacaftor/Tezacaftor. This is one of the few studies to assess adherence to CFTR modulators and symptomatic treatment longitudinally. CF patient therapy is expensive, and the assessment of variables with the highest importance for a high MPR, helped by new Machine learning tools, can contribute to defining new efficient TA strategies with higher benefits.
RESUMEN
Imipenem combined with beta-lactamase inhibitor relebactam (IMI/REL) has an extensive bactericidal activity againstGram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase3 clinical trial (RESTORE-IMI-2), double-blind, randomized,evaluated IMI/REL vs. piperacillin-tazobactam (PIP/TAZ) fortreatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), demonstrated non-inferiorityat all-cause mortality at 28 days (15.9% vs 21.3%), favorable clinical response at 7-14 days end of treatment (61% vs59.8%) and with minor serious adverse effects (26.7% vs 32%).IMI/REL is a therapeutic option in HAP and VAP at approveddosage imipenem 500 mg, cilastatin 500 mg and relebactam250 mg once every 6h, by an IV infusion over 30 min (AU)